177Lu-Dotatate Is a Viable Treatment in Meningioma

TREATMENT WITH LUTETIUM 177 dotatate (177Lu-dotatate; Lutathera) showed activity and met the progression-free survival (PFS) end point in patients with surgery- or radiation-refractory grade 2/3 meningioma, according to data from a prospective phase 2 trial presented during the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting in Washington, DC.1 The median PFS was 11.5 months, and the 2-year PFS rate was 26.7% (95% CI, 12%-58%). The clinical outcomes benchmark was the Response Assessment in Neuro-Oncology, which was the systematic review of 47 studies to establish the 6-month PFS (PFS-6) benchmarks for future trial designs. "[177Lu-dotatate] demonstrated clinically meaningful outcomes across a broad patient population, marking a significant milestone for refractory meningioma," Merrell concluded.